What Quality Does Pharma Expect in Multicenter FDG-PET Studies?
Quality FDG PET Multicenter
The Changing Landscape of Lymphoma Response Criteria
EMA’s Pharmacovigilance and Risk Assessment Committee (PRAC) on Linear Gadolinium Compounds
iRECIST Modified RECIST for Immunotherapy
Assessment Criteria for Solid Tumors in Immunotherapies
Local Clinical Trial Reads and Centralized Clinical Trial Reads
Quality Management of PET/CT Scanners: International Standards and EARL Experiences
Interested in PINTaD Meetings prior to 2013?
Additional materials and presentations may be downloaded below.